TW200630356A - Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole - Google Patents
Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazoleInfo
- Publication number
- TW200630356A TW200630356A TW094138274A TW94138274A TW200630356A TW 200630356 A TW200630356 A TW 200630356A TW 094138274 A TW094138274 A TW 094138274A TW 94138274 A TW94138274 A TW 94138274A TW 200630356 A TW200630356 A TW 200630356A
- Authority
- TW
- Taiwan
- Prior art keywords
- polymorphic forms
- phenylsulfanyl
- methylcarbamoyl
- indazole
- ethenyl
- Prior art date
Links
- WRSXUNSJGJUKHE-UHFFFAOYSA-N indazole Chemical compound C1=CC=C[C]2C=NN=C21 WRSXUNSJGJUKHE-UHFFFAOYSA-N 0.000 title abstract 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 title abstract 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62466504P | 2004-11-02 | 2004-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200630356A true TW200630356A (en) | 2006-09-01 |
Family
ID=35538878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094138274A TW200630356A (en) | 2004-11-02 | 2005-11-01 | Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060094763A1 (OSRAM) |
| EP (1) | EP1819696A1 (OSRAM) |
| JP (1) | JP2008518904A (OSRAM) |
| KR (1) | KR20070060145A (OSRAM) |
| AR (1) | AR051945A1 (OSRAM) |
| AU (1) | AU2005300317A1 (OSRAM) |
| BR (1) | BRPI0517924A (OSRAM) |
| CA (1) | CA2586177A1 (OSRAM) |
| IL (1) | IL182580A0 (OSRAM) |
| MX (1) | MX2007005273A (OSRAM) |
| RU (1) | RU2007116150A (OSRAM) |
| TW (1) | TW200630356A (OSRAM) |
| WO (1) | WO2006048751A1 (OSRAM) |
| ZA (1) | ZA200702976B (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1885338A1 (en) * | 2005-05-19 | 2008-02-13 | Pfizer, Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| KR101237588B1 (ko) † | 2007-04-05 | 2013-02-27 | 화이자 프로덕츠 인코포레이티드 | 포유동물에서의 비정상적인 세포 생장의 치료에 적합한 6-〔2-(메틸카바모일)페닐설파닐〕-3-ｅ-〔2-(피리딘-2-일)에테닐〕인다졸의 결정질 다형체 |
| KR20140069297A (ko) | 2011-09-30 | 2014-06-09 | 화이자 인코포레이티드 | N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물 |
| BR112014011453A2 (pt) | 2011-11-11 | 2017-05-02 | Pfizer | n-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida para o tratamento de leucemia mielógena crônica |
| EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
| CN104140414B (zh) * | 2013-05-07 | 2018-12-11 | 江苏豪森药业集团有限公司 | 阿昔替尼晶型的制备方法 |
| WO2015067224A1 (en) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole |
| CN118286440A (zh) | 2014-02-04 | 2024-07-05 | 辉瑞大药厂 | 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合 |
| US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| BR112017018234A2 (pt) | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| WO2016178150A1 (en) * | 2015-05-05 | 2016-11-10 | Shilpa Medicare Limited | Novel polymorphs of axitinib |
| KR102712880B1 (ko) | 2015-06-16 | 2024-10-02 | 메르크 파텐트 게엠베하 | Pd-l1 길항제 조합 치료 |
| MX2019003755A (es) | 2016-10-06 | 2019-08-12 | Pfizer | Regimen de dosificacion de avelumab para el tratamiento de cancer. |
| WO2020003196A1 (en) * | 2018-06-28 | 2020-01-02 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of axitinib |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| JP7200399B2 (ja) | 2019-04-18 | 2023-01-06 | シントン・ビー．ブイ． | アキシチニブの製造方法、中間体２－（（３－ヨード－１ｈ－インダゾール－６－イル）チオ）－ｎ－メチルベンズアミドの精製方法、アキシチニブ塩酸塩によるアキシチニブの精製方法、アキシチニブ塩酸塩の固体形態 |
| JP2022532540A (ja) | 2019-05-09 | 2022-07-15 | シントン・ビー．ブイ． | アキシチニブを含有する医薬組成物 |
| EP3884929B1 (en) | 2020-03-25 | 2023-06-14 | Ocular Therapeutix, Inc. | Ocular implant containing a tyrosine kinase inhibitor |
| CN113943271B (zh) * | 2020-07-15 | 2023-11-14 | 鲁南制药集团股份有限公司 | 一种阿昔替尼晶型及其制备方法 |
| CN112174933A (zh) * | 2020-08-07 | 2021-01-05 | 天津理工大学 | 一种阿西替尼富马酸盐的新晶型及其制备方法 |
| CN114685436B (zh) * | 2020-12-25 | 2022-12-02 | 鲁南制药集团股份有限公司 | 阿昔替尼糖精共晶水合物 |
| CN114685437B (zh) * | 2020-12-25 | 2022-12-09 | 鲁南制药集团股份有限公司 | 阿昔替尼与糖精共晶 |
| CN114685431B (zh) * | 2020-12-26 | 2022-11-29 | 鲁南制药集团股份有限公司 | 一种阿昔替尼柠檬酸盐晶型 |
| CN114685438B (zh) * | 2020-12-28 | 2023-06-13 | 鲁南制药集团股份有限公司 | 一种阿昔替尼苹果酸新盐 |
| CN114685432B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 阿昔替尼盐晶型及其制备方法 |
| CN114685433B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 一种阿昔替尼香草酸共晶盐及其制备 |
| CN114685435B (zh) * | 2020-12-28 | 2023-01-31 | 鲁南制药集团股份有限公司 | 阿昔替尼马来酸盐晶型及其制备 |
| MX2024010773A (es) | 2022-03-03 | 2024-09-10 | Pfizer | Anticuerpos multiespecificos y usos de estos. |
| EP4282415A1 (en) | 2022-05-26 | 2023-11-29 | Genepharm S.A. | A stable tablet composition of axitinib |
| IL322360A (en) | 2023-04-11 | 2025-09-01 | Ocular Therapeutix Inc | Intraocular implant containing axitinib iv polymorph |
| KR20250108329A (ko) | 2024-01-08 | 2025-07-15 | (주)유케이케미팜 | 엑시티닙의 제조방법 |
| WO2025157389A1 (en) | 2024-01-22 | 2025-07-31 | Iomx Therapeutics Ag | Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors |
| KR20250150872A (ko) | 2024-04-12 | 2025-10-21 | 주식회사 스카이테라퓨틱스 | 액시티닙의 신규 분자 회합체 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
-
2005
- 2005-10-21 EP EP05796896A patent/EP1819696A1/en not_active Withdrawn
- 2005-10-21 WO PCT/IB2005/003312 patent/WO2006048751A1/en not_active Ceased
- 2005-10-21 MX MX2007005273A patent/MX2007005273A/es not_active Application Discontinuation
- 2005-10-21 RU RU2007116150/04A patent/RU2007116150A/ru not_active Application Discontinuation
- 2005-10-21 JP JP2007538541A patent/JP2008518904A/ja active Pending
- 2005-10-21 CA CA002586177A patent/CA2586177A1/en not_active Abandoned
- 2005-10-21 BR BRPI0517924-6A patent/BRPI0517924A/pt not_active IP Right Cessation
- 2005-10-21 KR KR1020077010040A patent/KR20070060145A/ko not_active Ceased
- 2005-10-21 AU AU2005300317A patent/AU2005300317A1/en not_active Abandoned
- 2005-10-31 US US11/264,493 patent/US20060094763A1/en not_active Abandoned
- 2005-11-01 TW TW094138274A patent/TW200630356A/zh unknown
- 2005-11-01 AR ARP050104569A patent/AR051945A1/es unknown
-
2007
- 2007-04-11 ZA ZA200702976A patent/ZA200702976B/xx unknown
- 2007-04-16 IL IL182580A patent/IL182580A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007005273A (es) | 2007-07-19 |
| AR051945A1 (es) | 2007-02-21 |
| ZA200702976B (en) | 2008-08-27 |
| EP1819696A1 (en) | 2007-08-22 |
| US20060094763A1 (en) | 2006-05-04 |
| IL182580A0 (en) | 2007-07-24 |
| AU2005300317A1 (en) | 2006-05-11 |
| KR20070060145A (ko) | 2007-06-12 |
| BRPI0517924A (pt) | 2008-10-21 |
| WO2006048751A1 (en) | 2006-05-11 |
| JP2008518904A (ja) | 2008-06-05 |
| RU2007116150A (ru) | 2008-11-10 |
| CA2586177A1 (en) | 2006-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200630356A (en) | Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole | |
| TW200630360A (en) | Polymorphs of {5-[3-(4,6-difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine | |
| EA020703B9 (ru) | Пиразолохиназолины | |
| WO2009006389A3 (en) | Pyrimidine derivatives useful as raf kinase inhibitors | |
| WO2007127505A3 (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
| WO2005063820A3 (en) | Il-7 fusion proteins | |
| TN2009000128A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
| WO2007143434A3 (en) | Indazole and isoindole derivatives as glucokinase activating agents | |
| WO2005004818A3 (en) | Heterocyclic compounds and their use as anticancer agents | |
| WO2007100880A8 (en) | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors | |
| GEP20146101B (en) | Pyridine and pyrazine derivatives as protein kinase modulators | |
| WO2007013896A3 (en) | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors | |
| MX2010004244A (es) | Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk). | |
| ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
| MX2009004714A (es) | Derivados de pirazol fusionado 3-aminocarbonilo sustituidos como moduladores de proteina cinasa. | |
| WO2007103370A3 (en) | Quinazoline derivatives as phosphodiesterase 10 inhibitors | |
| ATE528302T1 (de) | 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind | |
| SG162747A1 (en) | Erythropoietin receptor peptide formulations and uses | |
| MX2008011175A (es) | Inhibidores de fosfodiesterasa 10. | |
| WO2009038385A3 (en) | Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same | |
| WO2005086656A3 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| MA33290B1 (fr) | Pipéridines substituées | |
| WO2006133104A3 (en) | Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists | |
| MA33291B1 (fr) | Pipéridines substituées | |
| TW200833337A (en) | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline |